- Investor Relations
- SGX Announcements
- General Announcement: Hyphens Pharma’s TDF Blu Voile Sunscreen
Hyphens Pharma’s TDF® Blu Voile sunscreen scientifically proven to protect skin against blue light at cellular level
- Clinical study on the protective effects of TDF® Blu Voile Sunscreen published in International Journal of Cosmetic Science
Singapore, 15 September 2022 – Hyphens Pharma International Limited (“Hyphens Pharma”, “凯帆药剂国际有限公司”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce results of a clinical study on “The protective effect of a novel sunscreen against blue light”, published recently in the International Journal of Cosmetic Science, shows that its TDF® Blu Voile Sunscreen provides 82% protection at the cellular level against the harmful effects of blue light irradiation, it also offers thorough and complete protection against UV-A/UV-B and blue light, versus conventional broad-spectrum sunscreens.1
Mr Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma commented: “With the goal to be Asia’s No. 1 skin health company, Hyphens Pharma adopts a scientific approach to product innovation and development, and constantly aims to introduce products with strong therapeutic efficacy to help consumers address specific skincare issues. We introduced our TDF® Blu Voile Sunscreen as we needed a cutting-edge product that helps consumers guard against the harmful effects of skin exposure to both UV and blue light”.
What is Blue Light?
Traditionally, the focus has been placed on UV-A and UV-B protection in typical sunscreens as excessive UV-A and UV-B exposure causes skin damage which includes sunburn photoaging, pigmentation, photo dermatoses, and skin cancer. However, it was recently discovered that as a major component of solar radiation, high-energy visible (HEV) light, also referred to as blue light, was also an important contributor to photoaging. Studies were conducted to assess the effect of visible light on immediate pigmentation and delayed tanning when compared with long wavelength UV-A (UV-A1) irradiation. The results reported showed that visible light can induce pigmentation, and the pigmentation induced by visible light was darker and more sustained compared with UV-A1.2
TDF® Blu Voile Sunscreen is an advanced physical sunscreen that contains a unique blue light blocker that filters more than 90% of blue light with protection against UV rays3 (SPF50 PA+++ rating). Light in texture and easy to apply, TDF® Blu Voile Sunscreen has shown proven efficacy to protect the skin against photodamage and hyperpigmentation1, while being enhanced with moisturizing agents which hydrate, soothe and boost skin radiance, while being oil and alcohol free.
TDF® Blu Voile Sunscreen is available at dermatologist clinics, GP clinics, Skin GP clinics and Hospital retail pharmacies.
Dr Paul Chia, Dermatologist at The Dermatology Practice – Skin Hair Allergy Laser, said: “Blue light penetrates deeper into the skin to cause hyperpigmentation, such as melasma. Melasma is an acquired hyperpigmentation skin disorder that typically affects sun-exposed areas of the skin, it is a psychologically debilitating skin condition that is prevalent among Asian women. Based on the recent publication, the result has shown that TDF® Blu Voile has better protection against blue light induced pigmentation as compared to a conventional sunscreen, which is an important parameter when it comes to sunscreen selection”.
1 Francois-Newton V, et al. Int J Cosmet Sci. 2022 Aug;44(4):464-476
2 Mahmoud et.al. J Invest Dermatol. 2010 Aug;130(8):2092–7
3 Data on file, Hyphens Pharma Pte. Ltd.
About Hyphens Pharma International Limited
Hyphens Pharma International Limited and its subsidiaries (the “Group“) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea and Sri Lanka.
Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients’ homes.
For more information, please visit https://www.hyphensgroup.com
Issued on behalf of Hyphens Pharma International Limited
For enquiries, please contact:
Mr Ivan Hong, Tel: (65) 6704 9287 , Mob: (65) 9055 8883, Email: [email protected]
Mr Gerald Woon, Tel: (65) 6704 9268, Mob: (65) 9694 8364, Email: [email protected]
This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.
The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.